Last reviewed · How we verify
amoxicillin and metronidazole
This combination uses amoxicillin to inhibit bacterial cell wall synthesis and metronidazole to disrupt anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic and anaerobic pathogens.
This combination uses amoxicillin to inhibit bacterial cell wall synthesis and metronidazole to disrupt anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic and anaerobic pathogens. Used for Mixed aerobic-anaerobic bacterial infections, Helicobacter pylori eradication (as part of triple or quadruple therapy), Periodontal infections.
At a glance
| Generic name | amoxicillin and metronidazole |
|---|---|
| Also known as | Flagyl® 400 Filmtablette, Amoxicillin-ratiopharm® 500 |
| Sponsor | University of Campinas, Brazil |
| Drug class | Combination antibiotic (beta-lactam + nitroimidazole) |
| Target | Bacterial cell wall (penicillin-binding proteins) and anaerobic bacterial DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that binds to penicillin-binding proteins and inhibits peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Metronidazole is a nitroimidazole that generates reactive intermediates in anaerobic organisms, causing DNA strand breaks and cell death. Together, they provide synergistic coverage for mixed aerobic-anaerobic infections.
Approved indications
- Mixed aerobic-anaerobic bacterial infections
- Helicobacter pylori eradication (as part of triple or quadruple therapy)
- Periodontal infections
- Intra-abdominal infections
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Metallic taste (metronidazole)
- Allergic reaction (amoxicillin)
- Headache
Key clinical trials
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amoxicillin and metronidazole CI brief — competitive landscape report
- amoxicillin and metronidazole updates RSS · CI watch RSS
- University of Campinas, Brazil portfolio CI